Abstract:Avibactam is a non-β-lactam, β-lactamase inhibitor of the diazabicyclooctane class that covalently acylates its β-lactamase targets, encompassing extended spectrum of activities that cover serine β-lactamases but not metallo-β-lactamases. Ceftazidime and avibactam have complementary pharmacokinetic (PK) profiles. Both drugs have a half-life of approximately 2 h, making them suitable to be combined in a fixed-dose combination ratio of 4:1 (ceftazidime:avibactam). Renal clearance is the primary elimination pathway of both ceftazidime and avibactam, and dose adjustment is required in patients with moderate and severe renal impairment. Population PK models of ceftazidime and avibactam were developed separately and incorporated body weight, disease state, ethnicity, and renal function (creatinine clearance) as covariates of clearance and volume of distribution. The clinical dosing regimen of ceftazidime/avibactam combination was determined from population PK model simulations in the patient population for dosing regimens that can achieve sufficient joint probability of target attainment for ceftazidime minimum inhibitory concentration (MIC) of 8 mg/L at a fixed 4 mg/L avibactam concentration (MIC ≤ 8/4 mg/L); 8 mg/L is the breakpoint of ceftazidime in Enterobacteriaceae and Pseudomonas aeruginosa for the target pharmacodynamic indices of ceftazidime and avibactam of 50% time at which the free ceftazidime concentration is above the MIC (fT > MIC) and 50% time at which the free avibactam is above a threshold concentration of 1 mg/L (fT > CT). Whereas the static index approach does not take into account the changing potency of ceftazidime in the presence of changing avibactam concentration, a mathematical model based on kill-curve kinetics was utilized to validate the dose selection in humans. The clinical dosing regimen of 2/0.5 g ceftazidime/avibactam administered every 8 h as a 2-h intravenous infusion in patients with normal renal function, with dose adjustment in renal impairment, demonstrated statistical non-inferiority to carbapenem in phase III studies on the treatment of complicated intra-abdominal infection, complicated urinary tract infection, and nosocomial pneumonia, including ceftazidime non-susceptible Gram-negative pathogens. The success of the phase III studies validated the dose selection and exposure target that were associated with efficacy based on a model-informed approach.

Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae.

Comparative Metabolomics Reveals Key Pathways Associated With the Synergistic Killing of Colistin and Sulbactam Combination Against Multidrug-Resistant Acinetobacter baumannii .

Efficacy of synergistic antibiotic combinations against KPC-2 carbapenemase producing Klebsiella pneumoniae strains

Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against Acinetobacter baumannii in Patients with Hospital-Acquired Pneumonia

In vitro Pharmacokinetics/Pharmacodynamics Evaluation of Fosfomycin Combined with Amikacin or Colistin against KPC2-Producing Klebsiella pneumoniae.

In vitro and in vivo synergistic antibacterial activity of cefotaxime/sulbactam

Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Acinetobacter baumannii Using Checkerboard Information.

Pharmacodynamic Target Attainment of Seven Antimicrobials Against Gram-negative Bacteria Collected from China in 2003 and 2004.

Antibacterial Effect Evaluation of Moxalactam Against Extended-Spectrum Β-Lactamase-producing Escherichia Coli and Klebsiella Pneumoniae with in Vitro Pharmacokinetics/pharmacodynamics Simulation

Tracking Cefoperazone/Sulbactam Resistance Development in Vivo in A. Baumannii Isolated from a Patient with Hospital-Acquired Pneumonia by Whole-Genome Sequencing

In vitro activity of different ratios from matching cefotaxime/culbactam

Quantifying combined effects of colistin and ciprofloxacin against Escherichia coli in an in silico pharmacokinetic-pharmacodynamic model

The Combination Effect of Meropenem/sulbactam/polymyxin-B on the Pharmacodynamic Parameters for Mutant Selection Windows Against Carbapenem-Resistant Acinetobacter Baumannii

Pharmacokinetic/Pharmacodynamic Evaluation of Aztreonam/Amoxicillin/Clavulanate Combination Against New Delhi Metallo-β-Lactamase and Serine-β-Lactamase Co-Producing Escherichia Coli and Klebsiella Pneumoniae

Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria

Simulating Moxalactam Dosage for Extended-Spectrum Β-Lactamase-producing Enterobacteriaceae Using Blood Antimicrobial Surveillance Network Data.

Antibacterial Activities of Different Concentration Ratio of Cefotaxim-Sulbactam Against the Pathogenic Microorganisms

Aztreonam/avibactam Effect on Pharmacodynamic Indices for Mutant Selection of Escherichia Coli and Klebsiella Pneumoniae Harbouring Serine- and New Delhi Metallo-Β-lactamases.

Cefepime Combined with Amoxicillin/clavulanic Acid: a New Choice for the KPC-producing K. Pneumoniae Infection

In vitro effect of cefoperazone-sulbactam (2:1, 1: 1) combined with minocycline on imipenem-resistant Acinetobacter baumannii clinical isolates

Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime–Avibactam Combination: A Model-Informed Strategy for its Clinical Development